Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income margin | (252.2%) | (338.9%) | (423.8%) | (388.4%) | (7,198.9%) | (3,047.6%) | (777.1%) | (170.1%) | (252.3%) | (487.9%) | (844.4%) | 0.0% | (1,078.7%) | (50.7%) | 21.9% | (6,766.4%) | (6,185.2%) | (4,764.3%) | (10,235.6%) | 0.0% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Operating Income margin is 77,226.4%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Operating Income margin for Summit Therapeutics Inc. have been 31,404.0% over the past three years, and 22,076.5% over the past five years.
As of today, Summit Therapeutics Inc.'s Operating Income margin is 77,226.4%, which is higher than industry median of (915.3%). It indicates that Summit Therapeutics Inc.'s Operating Income margin is Good.